Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2022088484 - POLYPEPTIDE MONOMÈRE FC ET SON UTILISATION

Numéro de publication WO/2022/088484
Date de publication 05.05.2022
N° de la demande internationale PCT/CN2020/141250
Date du dépôt international 30.12.2020
CIB
C07K 16/00 2006.1
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
16Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C40B 40/10 2006.1
CCHIMIE; MÉTALLURGIE
40TECHNOLOGIE COMBINATOIRE
BCHIMIE COMBINATOIRE; BIBLIOTHÈQUES, p.ex. CHIMIOTHÈQUES, BIBLIOTHÈQUES VIRTUELLES (IN SILICO)
40Bibliothèques en soi, p.ex. matrices, mélanges
04Bibliothèques comprenant uniquement des composés organiques
10Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/642
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
642the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
A61K 47/6801
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Déposants
  • 苏州复融生物技术有限公司 SUZHOU FORLONG BIOTECHNOLOGY CO., LTD. [CN]/[CN]
Inventeurs
  • 应天雷 YING, Tianlei
  • 吴艳玲 WU, Yanling
  • 王春雨 WANG, Chunyu
Mandataires
  • 北京知果之信知识产权代理有限公司 BEIJING TRUST OF ZHIGUO IP AGENCY CO., LTD.
Données relatives à la priorité
202011161007.327.10.2020CN
Langue de publication Chinois (zh)
Langue de dépôt chinois (ZH)
États désignés
Titre
(EN) FC MONOMER POLYPEPTIDE AND APPLICATION THEREOF
(FR) POLYPEPTIDE MONOMÈRE FC ET SON UTILISATION
(ZH) 一种Fc单体多肽及其应用
Abrégé
(EN) Provided is an Fc monomer polypeptide, comprising CH2 and CH3 domains, the Fc monomer polypeptide comprising an amino acid sequence shown in SEQ ID NO: 1; X0 is L or S; X1 is any one amino acid among C, G, S, L, N, D, F, I, V, Y, Q, K, E, M, T or R; X2 is any one amino acid among H, L, Q, N, D, Y, R, C, G, S, F, T, I, V, A, K or M; X3 is any one amino acid among P, N, T, I, S, M, Q, R, L, G, V, A, E, D, Y, F, H or K; X4 is any one amino acid among K, N, S, I, M, E, Q, L, V, A, H, D, Y, F or T; and X5 is M or Y. Beneficial effects: a class of IgG Fc monomer polypeptides is obtained, the molecular weight thereof is only half of that of a wild type Fc region, the FcRn binding function of an antibody is reserved, and efficient expression in prokaryotic cells can be achieved.
(FR) L'invention concerne un polypeptide monomère Fc, comprenant des domaines CH2 et CH3, le polypeptide monomère Fc comprenant une séquence d'acides aminés représentée dans SEQ ID NO : 1; X0 représente L ou S; X1 est un quelconque acide aminé parmi C, G, S, L, N, D, F, I, V, Y, Q, K, E, M, T ou R; X2 représente un quelconque acide aminé parmi H, L, Q, N, D, Y, R, C, G, S, F, T, I, V, A, K ou M; X3 représente un quelconque acide aminé parmi P, N, T, I, S, M, Q, R, L, G, V, A, E, D, Y, F, H ou K; X4 représente un quelconque acide aminé parmi K, N, S, I, M, E, Q, L, V, A, H, D, Y, F ou T; et X5 représente M ou Y. Les effets bénéfiques : une classe de polypeptides monomères Fc d'IgG est obtenue, le poids moléculaire de celle-ci est seulement la moitié de celle d'une région Fc de type sauvage, la fonction de liaison à FcRn d'un anticorps est conservée, et une expression efficace dans des cellules procaryotes peut être obtenue.
(ZH) 提供一种Fc单体多肽,包含CH2和CH3结构域,所述Fc单体多肽包含SEQ ID NO:1所示的氨基酸序列,其中,X0为L或S,X1为C,G,S,L,N,D,F,I,V,Y,Q,K,E,M,T或R中的任一种氨基酸,X2为H,L,Q,N,D,Y,R,C,G,S,F,T,I,V,A,K或M中的任一种氨基酸,X3为P,N,T,I,S,M,Q,R,L,G,V,A,E,D,Y,F,H或K中的任一种氨基酸,X4为K,N,S,I,M,E,Q,L,V,A,H,D,Y,F或T中的任一种氨基酸,X5为M或Y。有益效果:获得一类IgG Fc单体多肽,其分子量仅为野生型Fc区域的一半,保留了抗体的FcRn结合功能,并可实现原核细胞中高效表达。
Documents de brevet associés
Dernières données bibliographiques dont dispose le Bureau international